C4 Therapeutics, Inc.

General Information

We are a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins to treat cancer, neurodegenerative conditions and other diseases. We leverage our proprietary technology platform called TORPEDO (Target ORiented ProtEin Degrader Optimizer) to synthesize a new class of small molecule protein degraders that are designed to selectively and efficiently destroy disease-causing proteins, including targets previously considered to be undruggable.

We are using our TORPEDO platform to build a robust pipeline of oral protein degradation drug candidates, with our lead product candidates focused on oncology indications. One of our lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma, or MM; peripheral T-cell lymphoma, or PTCL, and mantle cell lymphoma, or MCL. 

Industry: Pharmaceuticals
Employees: 88
Founded: 2015
Contact Information
Address 490 Arsenal Way, Suite 200 Watertown, MA 02472
Phone Number 617) 231-0700
Web Address http://www.c4therapeutics.com/
View Prospectus: C4 Therapeutics, Inc.
Financial Information
Market Cap $693.09mil
Revenues $0 mil (last 12 months)
Net Income $-34.1 mil (last 12 months)
IPO Profile
Symbol CCCC
Exchange NASDAQ
Shares (millions): 9.6
Price range $19.00 - $19.00
Est. $ Volume $182.4 mil
Manager / Joint Managers Jefferies/ Evercore/ BMO Capital Markets/ UBS Investment Bank
Expected To Trade: 10/2/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change